Get the Stockscreener App
5.27
0.30%
-0.04
Vanda Pharmaceuticals Inc stock is traded at $5.27, with a volume of 48,612.
It is down -0.30% in the last 24 hours and up +17.38% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$5.31
Open:
$5.35
24h Volume:
48,612
Relative Volume:
0.10
Market Cap:
$311.99M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
100.57
EPS:
0.0524
Net Cash Flow:
$12.42M
1W Performance:
-1.96%
1M Performance:
+17.38%
6M Performance:
+28.18%
1Y Performance:
+19.23%
1-Day Range:
$5.26
$5.40
1-Week Range:
$5.22
$5.59
52-Week Range:
$3.8092
$5.59
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.28 | 313.76M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
What high frequency data says about Vanda Pharmaceuticals Inc.Weekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Sierra vs. Radivojevic | Final Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Is Vanda Pharmaceuticals Inc a good long term investmentSector Performance Review & Ride the Trends That Billionaires Follow - earlytimes.in
Real time scanner hits for Vanda Pharmaceuticals Inc. explainedQuarterly Portfolio Report & AI Enhanced Execution Alerts - newser.com
Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group - WTA Tennis
Vanda Pharmaceuticals Inc. stock prediction for this weekWeekly Stock Report & Weekly Breakout Opportunity Watchlist - newser.com
Lazaro Garcia vs. Bejlek | Quarterfinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Sierra vs. Gorgodze | Quarterfinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Will Vanda Pharmaceuticals Inc. (VM4) stock remain on Wall Street radarProfit Target & Verified Stock Trade Ideas - newser.com
Radivojevic vs. Noha Akugue | Quarterfinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Predicting Vanda Pharmaceuticals Inc. trend using moving averagesJuly 2025 Intraday Action & Long-Term Investment Growth Plans - newser.com
Carle vs. Kostovic | Quarterfinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Using portfolio simulators with Vanda Pharmaceuticals Inc. included2025 Key Lessons & Daily Volume Surge Trade Alerts - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals Hits New 52-Week High of $5.59 - Markets Mojo
Leonsis’ MSE Taps Vanda Pharmaceuticals as Founding Partner in New DC Arena - The National Herald
How supply shortages influence Vanda Pharmaceuticals Inc. (VM4) stockJuly 2025 Sector Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Noha Akugue/Thamm vs. Sherif/Zidansek | Semifinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Relative strength of Vanda Pharmaceuticals Inc. in sector analysis2025 Earnings Surprises & Stepwise Trade Signal Implementation - newser.com
Will breakout in Vanda Pharmaceuticals Inc. lead to full recoveryJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Using RSI to spot recovery in Vanda Pharmaceuticals Inc.July 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Oliynykova vs. Radivojevic | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Kucmova vs. Bejlek | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Maleckova/Skoch vs. Jakupovic/Radisic | Semifinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Vanda signs on as NHL's 1st pharma patch sponsor in Islanders deal, inks DC arena partnership - Fierce Pharma
New York Islanders Name Vanda Pharmaceuticals as Team’s Jersey Patch Partner in Milestone NHL Agreement - NHL.com
New York Islanders Name Vanda Pharmaceuticals as Team's Jersey Patch Partner in Milestone NHL Agreement - PR Newswire
Vanda Pharmaceuticals, The New York Islanders New Jersey Sponsor - The Hockey News
Monumental S&E adds Vanda as founding partner for Capital One Arena - Sports Business Journal
Vanda Pharmaceuticals Named Founding Partner, Secures MNMT Studio | VNDA Stock News - Stock Titan
Monumental Sports, Vanda Pharmaceuticals team up for Capital One Arena branding deal - The Business Journals
Vanda Pharmaceuticals Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Maleckova/Skoch vs. Carle/Papamichail | Quarterfinals Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Semenistaja vs. Lazaro Garcia | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Gorgodze vs. Selekhmeteva | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Sierra vs. Maristany Zuleta De Reales | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Kostovic vs. Sherif | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Carle vs. Brancaccio | Round of 16 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Hodzic vs. Bejlek | Round of 32 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Gorgodze vs. Papamichail | Round of 32 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Lazaro Garcia vs. Zidansek | Round of 32 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Diaz Adrover vs. Kucmova | Round of 32 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Semenistaja vs. Kotliar | Round of 32 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Will Vanda Pharmaceuticals Inc. (VM4) stock sustain bullish trend into 2025New Guidance & Safe Entry Trade Reports - newser.com
Is Vanda Pharmaceuticals Inc. forming a reversal patternWeekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Class Action Update Bronstein, Gewirtz & Grossman, LLC Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH) - ACCESS Newswire
Published on: 2025-10-05 07:45:19 - newser.com
Norin vs. Spiteri | Qualifying Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Kostovic vs. Kazionova | Qualifying Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Brancaccio vs. Branstine | Round of 32 Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Liu vs. Kazionova | Qualifying Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2025 - WTA Tennis
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vanda Pharmaceuticals Inc Stock (VNDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):